Results 221 to 230 of about 5,807 (256)

Bispecific antibodies engage T cells for antitumor immunotherapy

Expert Opinion on Biological Therapy, 2011
Although considerable evidence supports the hypothesis that T cells play a critical role in the immune response against cancer, the ability to mount and sustain tumor-specific cellular responses in vivo remains a challenge. A strategy that harnesses the cytotoxic advantage of T cell therapy is the use of bispecific antibodies designed to engage and ...
Bryan D, Choi, Mingqing, Cai, Darell D, Bigner, Ankit I, Mehta, Chien-Tsun, Kuan, John H, Sampson   +5 more
openaire   +2 more sources

Blinatumomab: A novel, bispecific, T-cell engaging antibody

American Journal of Health-System Pharmacy, 2016
The pharmacology, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, safety and tolerability, and place in therapy of blinatumomab are reviewed.Blinatumomab is a novel, bispecific, T-cell engaging antibody that targets tumor-associated antigens CD19 and CD3.
Megan Brafford, May, Ashley, Glode
openaire   +2 more sources

Myeloma evades T cell-engaging therapies

Nature Cancer, 2023
Bruno Paiva, Jesús F. San-Miguel
openaire   +2 more sources

T cell receptor engagement can influence T cell motility

Transplantation Proceedings, 2001
Marelli-Berg, F M, Alvarez-Iglesias, M, Prodromidou, K, Lombardi, G, Frasca, L, Berg, L P, Lechler, R I   +6 more
openaire   +3 more sources

Bispecific T-cell engager therapy for gastrointestinal cancers

Cancer Letters
Though cancer immunotherapy has revolutionized the treatment of several tumor types, progress for immunotherapy in gastrointestinal (GI) tumors has been difficult. Recently, there have been rapid developments in bispecific T-cell engagers for the treatment of several hematologic malignancies.
Kyle A. Burton, Anastasia E. Metropulos, Suneel D. Kamath, Hidayatullah G. Munshi, Daniel R. Principe   +4 more
openaire   +2 more sources

TRISPECIFIC T CELL ENGAGERS

2021
KAROW MARGARET, YAU RICHARD, SHENG JACKIE   +2 more
openaire   +4 more sources

Bispecific T cell engagers

2021
KAROW MARGARET, YAU RICHARD, SHENG JACKIE   +2 more
openaire   +4 more sources

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Future Oncology, 2022
Valentina Gambardella, Martin Wermke, Taofeek Owonikoko   +2 more
exaly  

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody

Frontiers in Immunology, 2023
Harald Kolmar, Julius Grzeschik, Björn Hock   +2 more
exaly  

Tumor and T cell engagement by BiTE.

Discovery medicine, 2014
Cancer immunotherapy attempts to exploit the capability of the immune system to attack malignant cells. Recent results suggest that clinical responses in patients point to this new mechanism as potentially beneficial in harnessing the immune system for combating established malignancies.
openaire   +1 more source